Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The researchers report 24-month interim results of two multicenter phase III studies in previously untreated children with growth failure secondary to GH deficiency (GHD) that were paramount to the development of a new recombinant human GH (rh- GH, somatropin), approved as the first 'biosimilar' in Europe.

Study 1 consisted of 3 parts performed in 89 children.

Who Took Part

According to the abstract, 89 children were involved.

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

In design terms this was a randomized and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

The researchers report 24-month interim results of two multicenter phase III studies in previously untreated children with growth failure secondary to GH deficiency (GHD) that were paramount to the development of a new recombinant human GH (rh- GH, somatropin), approved as the first 'biosimilar' in Europe.

PubMed files the paper under topics including Age Determination by Skeleton, Body Height, Growth Disorders, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor Binding Proteins and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 89 children.

The publication is from 2007 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.